Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (2657)	9/26/2001 10:16:43 AM
From: tuck	Read Replies (1) \| Respond to of 4974

Not sure where to put this; more analysts to keep an eye on: >>NEW YORK--(BUSINESS WIRE)--Sept. 26, 2001--Dresdner Kleinwort Wasserstein (DrKW) today announced initiation of equity research coverage of the biotechnology industry sector by leading analyst Charles C. Duncan, Ph.D. The firm also announced key additions to its Healthcare Investment Banking team. Paul Adams, Head of Healthcare Investment Banking commented, ``DrKW is firmly committed to a leadership position in the global biopharmaceutical industry. Our integrated global approach leverages our traditional strength in Europe with the rapid expansion of our U.S. capabilities in investment banking, sales and trading and equity research.'' DrKW's coverage of ``genomics-enabled'' drug development companies includes: Celgene (Nasdaq: CELG - news), CuraGen (Nasdaq: CRGN - news), Exelixis (Nasdaq: EXEL - news), Human Genome Sciences (Nasdaq: HGSI - news), Millennium Pharmaceuticals (Nasdaq: MLNM - news), Myriad Genetics (Nasdaq: MYGN - news), Tularik (Nasdaq: TLRK - news), and Vertex Pharmaceuticals (Nasdaq: VRTX - news), all rated Buy; and Celera Genomics (NYSE:CRA - news) and Sangamo BioSciences (Nasdaq: SGMO - news), rated Add. Dr. Duncan, a Director in Dresdner Kleinwort Wasserstein's Equity Research Division, has identified 10 companies that stand at a productivity inflection point and explained that these make up a small group of established firms that (1) have fully adopted the use of genomic information and the new tools of biology and (2) have shown early successes in establishing the potential for multiple product development -- both of which are key to generating superior rates of return for investors over the coming years. Dr. Duncan said, ``We are recommending investment in companies with excellent product development capabilities, a long list of product-oriented news flow, and truly exciting growth prospects. Moreover, as drug developers, these companies are relatively 'recession-resistant','' he noted. Before joining DrKW, Dr. Duncan was a senior analyst at Prudential Vector Healthcare. Dr. Duncan holds a Ph.D. in pharmaceutical sciences from the University of Colorado. Dresdner Kleinwort Wasserstein also announced the hiring of several senior investment bankers who bring over 40 years of biopharmaceutical experience into its Healthcare Group, creating an experienced M&A/strategic advisory capability for companies in the biotechnology and pharmaceutical sectors. These appointments include: Robert F. Carey, Managing Director. Mr. Carey has over a decade of prior experience working primarily with biotechnology and pharmaceutical companies at Vector Securities International, Inc. Mr. Carey was earlier with Shearson Lehman Hutton, Inc. and Ernst & Whinney. Jeffrey A. Fink, Managing Director. Mr. Fink has over 20 years of investment banking experience, the last ten of which were primarily focused in biopharmaceuticals. Prior to joining DrKW, Mr. Fink was responsible for biopharmaceutical M&A at Prudential Vector. Previously, Mr. Fink was head of Healthcare/Life Sciences investment banking at Tucker Anthony Cleary Gull, and from 1991 to 1999 was a senior investment banker at Vector Securities. In addition, Mr. Fink was with Smith Barney Harris Upham and Co. and Kidder Peabody & Co. Michael G. Page, Ph.D., Managing Director. Dr. Page spent 23 years in the Central Research unit of Pfizer Inc., ultimately as Vice President in charge of Medicinal Products Research in the U.S., prior to joining the Boston Consulting Group, and later, Vector Securities. Dr. Page holds Ph.D. and B.S. honors degrees from the University of Birmingham, England.<< snip Cheers, Tuck

To: nigel bates who wrote (2657)	9/27/2001 9:16:23 PM
From: Bob L	Read Replies (1) \| Respond to of 4974

Happened across the following announcement today. Apologize in advance if too old or otherwise unsuitable. Tuesday, August 14, 2001 By JOHN COOK SEATTLE POST-INTELLIGENCER REPORTER Despite a harsh market for initial public offerings, Bothell-based Northwest Biotherapeutics Inc. yesterday filed to raise as much as $48 million through a public stock sale. If successful, it would be only the third Washington state company to sell shares to the public this year. Seattle sandwich maker Briazz Inc. raised $16 million in May, while Bothell drug maker Seattle Genetics raised $49 million in March. Last year, 14 companies in the state went public, according to IPO Monitor. Northwest Biotherapeutics, an early-stage biotechnology company backed by Northwest Hospital, Progress Enterprises and Medarex Inc., is developing immunotherapy products to treat cancer. The company plans to ask the Federal Drug Administration for fast-track designation of DCVax-Prostate, an immunotherapy product in Phase 3 clinical trials that treats late-stage prostate cancer. About 198,100 new cases of prostate cancer will be diagnosed in the United States during 2001, according to The American Cancer Society. "Currently, the only FDA-approved treatments for hormone refractory prostate cancer are chemotherapy and radioactive pharmaceuticals, which can alleviate cancer-related symptoms but may cause significant adverse side effects and do not prolong survival. We believe that DCVax-Prostate addresses this critical unmet medical need," the company wrote in its filing with the Securities and Exchange Commission. The company also is working on products related to brain, lung and renal cancer -- though those initiatives are not as far along. Potential competitors include Cell Genesys Inc., Dendreon Corp. and Genzyme Molecular Oncology. The company plans to use money from the stock sale to pay for clinical trials, set up contract manufacturing relationships and pay a fee to Northwest Hospital. It recorded a $13.2 million net loss last year on revenues of $156,000. The company has not set pricing levels or a date for the offering, which is being underwritten by C.E. Unterberg, Towbin. The company employs 46 people. nwbio.com